Basaglar no longer covered through Pacific Source and Trillium.
- Details
- Published: Tuesday, 09 January 2024 12:10
- Written by 340B Editor
Basaglar (insulin glargine) will no longer be covered through Pacific Source(2/1/24) and Trillium (4/1/24). Alternative covered glargine formulations are Lantus and Rezvoglar. Encourage your patients to choose Lantus when switching from Basaglar. Lantus also has favorable 340B pricing.
|
Pacific Source Community Solution 2024 Insulin Change |
|||
|
Covered Now |
Must be switched to by 2/15 |
Conversion considerations |
|
|
Long acting |
Basaglar* |
Rezvoglar(insulin glargine-aglr) OR Lantus OR
Insulin degludec |
Consider insulin degludec U200 insulin for patients on 60 units/day or more. This will allow for a lower volume to be injected and for continuation of once daily dosing as this pen dials to 160units. Of note, U200 insulin pen dials in 2 unit increments. Insulin degludec has a longer half life, and missed doses can be injected late as long as there is 8 hrs until the next dose. As a reminder, basal insulin dosing should be capped at 0.5units/kg or FBG goal, whichever occurs first, to avoid overbasalization. A 20% dose reduction if switching to insulin degludec if patient currently controlled or at risk for hypoglycemia. After initial dose reduction, titrating back up may be necessary depending on response. |
- Basaglar cannot be changed automatically by the pharmacy to Rezvoglar or Lantus
Reported by:
Sara Jones, Pharm D.
Consulting Pharmacist
Northwest Human Services